I’m a board-certified pediatric rheumatologist and physician-scientist specializing in rheumatologic autoimmune and autoinflammatory conditions in children. I am an assistant professor of pediatrics at Cincinnati Children’s within the University of Cincinnati Department of Pediatrics. In this role, I serve as the rheumatology lead for the Cincinnati Children’s Multiple Sclerosis and Neuroimmunology Center. Before joining the faculty at Cincinnati Children’s in 2021, I led the pediatric rheumatology clinics and service at Johns Hopkins University and directed the multidisciplinary pediatric lupus clinic.
I strive to provide compassionate care. My philosophy is to “treat the child with a disease” and not focus on treating the disease alone. Having a rare disease is often isolating and challenging. I believe children and families should be supported through their journey. By providing a comprehensive and evidence-based approach to managing my patients, I aim to achieve the best possible outcomes. I believe in partnering with my patients and families and the primary care provider.
My research includes clinical and translational studies to improve outcomes for childhood-onset systemic lupus erythematosus (cSLE). In particular, I am studying how we can identify cSLE early and predict risks of severe outcomes. I also study how lupus affects the brain and nervous system, and its association with blood disorders such as antiphospholipid syndrome.
Throughout my career, I have been honored to receive several academic awards and recognitions. I was recognized as a Top Doctor by Baltimore Magazine in 2020.
I currently serve on the Pediatric Rheumatology Special Committee of the American College of Rheumatology (ACR). I am the co-chair of the American College of Rheumatology (ACR) Pediatric Residents Program. I serve on the advisory council of the Pediatric Rheumatology Collaborative Study Group (PRCSG).
I am a member of the Clinical Immunology Society, Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology European Association, American Academy of Pediatrics and the American Medical Women Association.
MD: University of Ibadan, Ibadan, Nigeria, 2005.
Residency: Morehouse School of Medicine, Atlanta, GA.
Chief Resident: Morehouse School of Medicine, Atlanta, GA.
Fellowship: Emory University, Atlanta, GA.
Master of Science in Clinical Research: Emory University, Atlanta, GA.
Certification: General Pediatrics; Pediatric Rheumatology.
Systemic lupus erythematosus; vasculitis; Kikuchi-Fujimoto’s disease; juvenile dermatomyositis; autoinflammatory disorders; systemic-onset juvenile idiopathic arthritis; macrophage activation syndrome; complex primary immune deficiencies and immune-dysregulation syndromes that overlap with rheumatologic diseases
Rheumatology, Lupus Center
Pediatric systemic lupus erythematosus - neuropsychiatric lupus; autoimmune cytopenias; antiphospholipid syndrome
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
An unusual presentation of chronic recurrent multifocal osteomyelitis involving bones of the skull. International Journal of Rheumatic Diseases. 2023; 26:1579-1581.
Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE. Lupus Science and Medicine. 2023; 10:e000884.
Treatment Guidelines in Pediatric Rheumatic Diseases. Rheumatic Disease Clinics of North America. 2022; 48:725-746.
International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology. 2022; 74:263-273.
Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort. Lupus. 2021; 30:1660-1670.
Lupus Mesenteric Vasculitis: A Rare Initial Presentation of Pediatric Systemic Lupus Erythematosus. Journal of Clinical Rheumatology: practical reports on rheumatic and musculoskeletal disease. 2021; 27:e181-e182.
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial. Trials. 2020; 21:887.